Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Kisspeptin-10

A fragment of the body's own reproductive signalling peptide, studied in human physiology research but not an approved therapy.

L3Early human studiesResearch / unapproved supply
Full profile

Nafarelin

A GnRH agonist that has been an approved nasal-spray medicine for decades — the standing rebuttal to 'nasal peptide means research chemical'.

L5Repeated human trialsApproved for a specific indication · FDA (US)
Full profile

How far human research has progressed

Kisspeptin-10

Human physiology research only; no approved product

Nafarelin

Long-approved medicine with extensive clinical history

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Kisspeptin-10

Not separately assessed; see the full profile.

Nafarelin

Not separately assessed; see the full profile.

Human research context

Kisspeptin-10

Human physiology research only; no approved product

Nafarelin

Long-approved medicine with extensive clinical history

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Kisspeptin-10

Strength of the human efficacy evidence35 of 100 evidence strength

Nafarelin

Strength of the human efficacy evidence82 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Kisspeptin-10

Strength of the animal and lab evidence55 of 100 evidence strength

Nafarelin

Strength of the animal and lab evidence75 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Kisspeptin-10

Strength of the human safety evidence35 of 100 evidence strength

Nafarelin

Strength of the human safety evidence80 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Kisspeptin-10

Check jurisdiction-specific details in the profile.

Not an FDA-approved therapy. The FDA's Pharmacy Compounding Advisory Committee concluded in October 2024 that the evidence and safety data were insufficient for the proposed compounding use (secondary hypogonadism) and weighed against including kisspeptin on the 503A bulk substances list.

Nafarelin

Named regulators: FDA (US)

FDA-approved nasal solution (Synarel) for central precocious puberty; endometriosis labelling has varied by market and label revision. Approval is indication-specific.

Common claims

Kisspeptin-10

  • · Restores reproductive hormone signalling in hypogonadism
  • · Investigational fertility applications

Nafarelin

  • · Manages central precocious puberty
  • · Historical use in endometriosis depending on market

How settled our evidence rating is

Kisspeptin-10

Low confidence in ratingL3Early human studies

Nafarelin

High confidence in ratingL5Repeated human trials

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Kisspeptin-10

Kisspeptin signalling has context-dependent roles in cancer biology, including metastasis-suppression research. This is mechanistic context, not a demonstrated risk or benefit of administration.

Nafarelin

No established human cancer signal within approved use.

What this adds up to, in plain English

Kisspeptin-10

Preliminary human observations exist, but they may not establish a treatment-attributable benefit.

Nafarelin

Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.